Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Antibody Optimization Service

In the process of antibody discovery, high affinity and low immunogenicity are key factors for the success of antibody therapy development, affecting the efficacy and safety of antibody drugs. Our company has rich experience in antibody optimization and is committed to helping customers make research progress in the development of rare disease antibody therapy.

Overview of Antibody Optimization

Antibody optimization can improve the selectivity and specificity of antibody drugs, help reduce drug dosage, and reduce drug side effects. Therefore, researching antibody optimization strategies in the discovery stage enables the acquisition of better antibody candidates before entering antibody production. With the development of antibody therapy for rare diseases, antibody optimization technology is also progressing. Researchers should choose appropriate antibody optimization technology according to the characteristics of rare diseases, to more efficiently prepare high-quality candidate antibodies.

2-2-4-2 Antibody Optimization Service-1Fig.1 Graphic summary of antibody optimization engineering (Lou, Hantao, et al. 2022)

Our Services

Our company has a variety of antibody optimization platforms to help rare disease antibody drug research and development and solve the current problems of antibody optimization.

  • Antibody Humanization

Antibody humanization can reduce the immunogenicity of monoclonal antibodies derived from xenogeneic sources and improve their activation of the human immune system by replacing non-human antibody frameworks with human ones.

2-2-4-2 Antibody Optimization Service-2Sequencing
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-4Design
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-5Production
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-6Characterization
  • Determination of affinity for antigen
  • 3D structure model building
  • Transfection, expression and purification
  • Analysis: SDS-PAGE, WB, UV280
  • Antibody Affinity Maturation

Affinity maturation is known to improve the antibody-antigen binding kinetics for drug optimization. Our company has developed a high-class affinity maturation service tailored to increase the affinity of your antibody against its target.

2-2-4-2 Antibody Optimization Service-7Antibody expression on phage surface
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-8Phage display library design
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-9Recombinant expression of the variants
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-6Antibody characterization
  • Establishment of custom phage display screening protocol
  • Creation of mutated genes library and phage display library
  • Gene synthesis and subcloning in an adapted expression vector
  • SEC-HPLC, DSC analysis;
  •  KD determination
  • Antibody Fc Engineering

The antibody efficacy and half-life can be improved by modifying the amino acid sequence of the Fc region. Our company provides a comprehensive range of Fc engineering services to meet your needs in antibody drug development for rare diseases.

2-2-4-2 Antibody Optimization Service-9Antibody production
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-10Affinity measurement
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-11SEC-HPLC analysis
2-2-4-2 Antibody Optimization Service-3
2-2-4-2 Antibody Optimization Service-12Cell-based functional assay
  • STR mutant
  • Fc function enhanced mutant
  • Fc domain mutant
  • Detect the affinity of mutants to the antigen(SPR)
  • SEC-HPLC analysis of mutant
  • ADCC assay
  • CDC assay
  • ADCP assay
  • Antibody Pharmacokinetic Improvement

Our company specializes in enhancing the pharmacokinetics of therapeutic antibodies, resulting in numerous benefits such as lower dosage requirements, the development of subcutaneous formulations, and reduced costs.

Optimization method Technologies used
Reduction of non-specific clearance
  • Decrease of the antibody's isoelectric point
Reduction of antigen binding-mediated clearance
  • Increase of the antibody's capacity to dissociate from the antigen in acidic environments
  • Increase antibody's binding at neutral pH, to FcRn and/or antigen
  • Antibody Pharmaceutical Properties Improvement

The improvement of antibody pharmaceutical properties helps to minimize immunogenicity, improve production efficiency to reduce the cost of goods, enable high-concentration formulation, and facilitate good quality control in manufacturing.

Optimization method Technologies used
Improvement of thermostability
  • Modification of amino acids in the VH/VL interface
  • Elimination of hydrophobic residues on the antibody surface
  • Optimizing conserved amino acid residues
Improvement of solubility
  • Decrease of the antibody's surface hydrophobicity
  • Altering the antibody's isoelectric point
  • Engineering the antibody with N-linked glycan introduction within a CDR sequence
Improvement of chemical stability
  • Prevention of antibody deamidation
  • Avoiding antibody isomerization
  • Prevention of succinimide formation
  • Prevention of methionine and tryptophan oxidation
  • Avoiding cysteinylation of unpaired cysteines in the CDR region
Reduction of heterogeneity
  • Prevention of antibody glycosylation and N-pyroglutamine cyclization

Our company has the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease therapy research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Lou, Hantao, et al. "Antibody variable region engineering for improving cancer immunotherapy." Cancer Communications 42.9 (2022): 804-827.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.